Pharmaceutical R&D productivity is widely perceived to be in trouble. As Big Pharma faces an industry-wide pipeline crunch coupled with patent expiry on key products and ever-increasing drug development costs, the values of late-stage licensing deals have soared. This feature considers the problem of R&D productivity and the changes made in case of collaborative R&D deal making in light of those problems.